Block & Leviton is investigating GeneDX Holdings Corp. (NYSE: WGS) for potential securities law violations. Investors who have lost money in their GeneDX ...
GeneDx Holdings Corp. has already reported first-quarter 2026 results, with revenue rising to US$102.25 million while net loss widened to US$63.32 million, and management cut full-year 2026 revenue ...
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” first-quarter 2026 ...
It also lowered expected exome and genome revenue growth to at least 20%, from 33–35%, while maintaining volume growth of at least 30%. ・Stueland added that the company remains confident in its ...
The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS) on behalf of investors concerning the Company's possible violations of ...
Zacks Investment Research on MSN
GeneDx Holdings Corp. (WGS) reports Q1 loss, lags revenue estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.28 per share a year ago. These ...
The World Health Organization (WHO) has released a guide for use of whole genome sequencing (WGS) in food safety. The guidance comes in three parts. The first explains the minimum capacity ...
On Nov.19, U.S. Space Command accepted Wideband Global SATCOM (WGS)-10 into the operational constellation and will be transitioning users to utilize the bandwidth provided by this new satellite.
Whole genome sequencing (WGS) provides a level of additional information that more than balances out the additional costs if used effectively, according to a recent study. Researchers evaluated costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results